SLC5A2 and type 2 diabetes mellitus: Empagliflozin is an inhibitor of SGLT2 in the kidney, which reduces glucose reabsorption and increases urinary glucose excretion, leading to improved glycemic control in patients with type 2 diabetes mellitus.